Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02604173 · ClinicalTrials.gov registry record · Phase 3
Altitude Sickness Prevention and Efficacy of Comparative Treatments
A Phase 3 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
NCT02604173: Completed Phase 3 study, sponsored by Stanford University.
NCT02604173 is a Phase 3 study that has completed, run by Stanford University. The registered enrollment target is 103 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02604173, a Phase 3 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study is designed to be the first to examine the novel drug budesonide for prevention of acute mountain sickness in comparison to acetazolamide and in the context of rapid ascent to high altitude. The investigators will accomplish these objectives with a prospective, double blinded view of a large population of hikers who are ascending at their own rate in a true hiking environment.
Interventions
- DRUG Placebo
- DRUG Acetazolamide
- DRUG Budesonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2016-08 |
| Est. Completion | 2016-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02604173
The ClinicalTrials.gov registry entry for NCT02604173 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02604173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02604173 about?
NCT02604173 is a clinical study titled "Altitude Sickness Prevention and Efficacy of Comparative Treatments". This study is designed to be the first to examine the novel drug budesonide for prevention of acute mountain sickness in comparison to acetazolamide and in the context of rapid ascent to high altitude. The investigators will accomplish these objectives with a prospective, double blinded view of a la...
What is the current status of trial NCT02604173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2016-08. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02604173?
The interventions under investigation include: Placebo (DRUG), Acetazolamide (DRUG), Budesonide (DRUG).
Who is sponsoring clinical trial NCT02604173?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.